Successful Xenograft of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Specimen from Human Extrahepatic Cholangiocarcinoma into an Immunodeficient Mouse

Se Young Jang*, Han Ik Bae†, In Kyu Lee*1,2, Hwan Ki Park3, and Chang-Min Cho*

Departments of *Internal Medicine, †Pathology, Kyungpook National University School of Medicine, BK21 Plus KNU Biomedical Convergence Program, and *Leading-Edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease (DMRC), Kyungpook National University Hospital, Daegu, Korea

Correspondence to: Chang-Min Cho
Center for Hepatobiliary and Pancreatic Cancer, Kyungpook National University Medical Center, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea
Tel: +82-53-200-2608, Fax: +82-53-200-2028, E-mail: cmcho@knu.ac.kr

Received on July 24, 2014. Revised on September 29, 2014. Accepted on November 10, 2014. Published online June 19, 2015
pISSN 1976-2283 eISSN 2005-1212 http://dx.doi.org/10.5009/gnl14279

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

CASE REPORT

A 65-year-old man who had previously been healthy was transferred to our clinic with a 2-week history of jaundice. Laboratory tests and a contrast-enhanced abdominal computed tomography scan had been performed at another hospital. These tests demonstrated hyperbilirubinemia and an enhancing mass at the distal common bile duct, with diffuse intra- and extrahepatic bile duct dilation (Fig. 1A and B). Before admission, percutaneous transhepatic biliary drainage for bile duct decompression was performed at another hospital. The patient was transferred to our clinic for further evaluation and treatment.

EUS examination revealed a round mass in the intrapancreatic bile duct, with hypoechoic areas and heterogeneous echogenicity. The mass measured 21×16 mm in maximal cross-sectional diameter. The endosonographic borders were well defined. After obtaining written informed consent for the procedures and potential risks, we performed a diagnostic needle aspiration of the mass. Color Doppler imaging was obtained prior to the needle puncture to confirm a lack of significant vascular structures within the needle path. Five passes were made with a 22-gauge needle (EchoTip; Cook Medical Inc., Winston-Salem, NC, USA) by a transduodenal approach (Fig. 1C). The specimens acquired from the first three passes were prepared for cytopathologic diagnosis, and those from the last two passes were used for the xenograft. Written informed consent for xenograft research was also obtained from the patient, and we received permission from the Institutional Review Board (number: KNUMC_14-1010).

The acquired FNA specimen was cut into a 2-mm cube and mixed with Matrigel (BD Biosciences, Bedford, MA, USA). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

CASE REPORT

A 65-year-old man who had previously been healthy was transferred to our clinic with a 2-week history of jaundice. Laboratory tests and a contrast-enhanced abdominal computed tomography scan had been performed at another hospital. These tests demonstrated hyperbilirubinemia and an enhancing mass at the distal common bile duct, with diffuse intra- and extrahepatic bile duct dilation (Fig. 1A and B). Before admission, percutaneous transhepatic biliary drainage for bile duct decompression was performed at another hospital. The patient was transferred to our clinic for further evaluation and treatment.

EUS examination revealed a round mass in the intrapancreatic bile duct, with hypoechoic areas and heterogeneous echogenicity. The mass measured 21×16 mm in maximal cross-sectional diameter. The endosonographic borders were well defined. After obtaining written informed consent for the procedures and potential risks, we performed a diagnostic needle aspiration of the mass. Color Doppler imaging was obtained prior to the needle puncture to confirm a lack of significant vascular structures within the needle path. Five passes were made with a 22-gauge needle (EchoTip; Cook Medical Inc., Winston-Salem, NC, USA) by a transduodenal approach (Fig. 1C). The specimens acquired from the first three passes were prepared for cytopathologic diagnosis, and those from the last two passes were used for the xenograft. Written informed consent for xenograft research was also obtained from the patient, and we received permission from the Institutional Review Board (number: KNUMC_14-1010).

The acquired FNA specimen was cut into a 2-mm cube and mixed with Matrigel (BD Biosciences, Bedford, MA, USA). The mixture of tumor tissue-Matrigel was implanted subcutaneously
into the flank of a 6-week-old female BALB/c-nu mouse (SLC Inc., Hamamatsu, Japan) that was anesthetized with isoflurane. All of the animal procedures were carried out in accordance with the institutional guidelines for animal research. After 6.5 months, a 1.3-cm$^3$ tumor was removed and analyzed (Fig. 2).

Histologic and immunohistochemical staining of the xenografted tumor demonstrated identical pathologic patterns to those of the human tumor (Fig. 3).

**DISCUSSION**

PDTX models have been established and are increasingly used for preclinical studies of chemotherapeutic responses. However, PDTX models for cholangiocarcinoma are relatively few in number and are limited in their degree of genetic characterization and validation.

Three models have been used to evaluate the preclinical response to new anticancer drugs: genetically engineered models, xenografts derived from human cell lines, and patient-derived xenografts. PDTX models are superior in reproducing the characteristics and clinical course of cancer. Xenografts that are derived from human cancer cell lines are more homogeneous and undifferentiated because of selection pressures occurring during long-term in vitro culture.

Some experimental trials for the treatment of bile duct cancers have been performed. In 1992, experimental chemotherapy for the treatment of xenografted human bile duct and gall bladder cancer cell lines was carried out in nude mice. In addition,
in 2003, one study reported the successful establishment and characterization of two xenograft models of human biliary tract cancer, using fresh cell lines that were created from surgical specimens of bile duct adenocarcinoma. However, these results are from xenografts that were derived from human tumor cell lines and do not sufficiently represent clinical cancer characteristics, especially with regard to metastasis and drug sensitivity.

This case report describes a successful patient-derived xenograft from bile duct cancer; it seems to be the first such report in bile duct cancer and is the first use of an EUS-FNA specimen to create the xenograft. In this case, the bile duct cancer featured mass formation and papillary growth, and the EUS-FNA specimen contained a large number of cancer cells.

Although most tumor tissues that are used in patient-derived xenografts have been obtained by surgical excision, it is difficult to obtain biliary cancer tissues by surgical excision for use in xenografting. Because malignant biliary tumors are usually advanced and inoperable at diagnosis, chemotherapy is usually the main treatment option. Furthermore, bile duct cancer is not only diverse in terms of anatomical location but is also diverse at the genetic level. Many studies have performed molecular and cellular analyses to investigate gene and protein expression in bile duct cancer.

Extrahepatic cholangiocarcinomas usually feature sclerosing or periductal infiltration and contain a large amount of fibrotic tissue. However, in this case, the cholangiocarcinoma was characterized by mass formation, which yielded more cancer cells in the aspirated specimen than the sclerosing or periductal infiltrating type. Unfortunately, it took a long time for the xenografted mass to reach a visible size. This result might be due to both the paucity of the inoculated tumor cells compared to the surgical specimen and characteristics of the slow-growing tumor itself. Further xenograft studies using more bile duct cancers are needed to improve technical skills and increase the yield of cancer cells.

As a first report of successful PDTX using EUS-FNA specimen, we expect that this case may contribute to the development of a tailored therapy for bile duct cancer in the future. However, further studies are required to shorten the growth period to obtain a sufficient volume of xenograft before applying clinical management.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This research was supported by a grant of the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant number: A111345).

REFERENCES

1. Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 2013;3:295.
2. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010;12:473-480.
3. Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: preclinical cancer drug development revisited. J Clin Invest 2013;123:3639-3645.
4. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 2005;333:216-222.
5. Tsubono M, Nio Y, Tseng CC, et al. Experimental chemotherapy for xenograft cell lines of human bile duct and gall bladder cancers in nude mice. J Surg Oncol 1992;51:274-280.
6. Emura F, Kamma H, Ghosh M, et al. Establishment and characterization of novel xenograft models of human biliary tract carcinomas. Int J Oncol 2003;23:1293-1300.
7. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013;73:5315-5319.
8. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002;16:77-85.

9. Tonini G, Virzì V, Fratto ME, Vincenzi B, Santini D. Targeted therapy in biliary tract cancer: 2009 update. Future Oncol 2009;5:1675-1684.

10. Amano R, Yamada N, Doi Y, et al. Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer. Anticancer Res 2010;30:4115-4121.